AAPL353.11+21.21 (+6.39%) ▲|ABBV285.72-0.28 (-0.10%) ▼|ABT114.57+5.17 (+4.73%) ▲|ACN265.25+10.69 (+4.20%) ▲|ADBE252.87+6.73 (+2.73%) ▲|AMAT370.29-11.63 (-3.05%) ▼|AMD486.66+2.76 (+0.57%) ▲|AMGN473.30+12.04 (+2.61%) ▲|AMT195.14+7.85 (+4.19%) ▲|AMZN266.71+16.02 (+6.39%) ▲|AVGO326.33-5.80 (-1.75%) ▼|AXP331.89+6.39 (+1.96%) ▲|BA176.92+3.61 (+2.08%) ▲|BAC51.57+1.91 (+3.85%) ▲|BKNG172.39+16.72 (+10.74%) ▲|BLK1,216.59+55.27 (+4.76%) ▲|BMY63.02+1.31 (+2.12%) ▲|BNY149.93+0.62 (+0.41%) ▲|BRK-B572.73+15.66 (+2.81%) ▲|C125.21+2.50 (+2.04%) ▲|CAT583.50-40.44 (-6.48%) ▼|CL99.32+3.70 (+3.87%) ▲|CMCSA24.91+1.24 (+5.22%) ▲|COF203.97-4.75 (-2.27%) ▼|COP137.90-6.50 (-4.50%) ▼|COST1,050.06+30.80 (+3.02%) ▲|CRM228.20+6.00 (+2.70%) ▲|CSCO102.61-0.36 (-0.35%) ▼|CVS81.22-10.19 (-11.15%) ▼|CVX217.92-7.35 (-3.26%) ▼|DE662.93-2.90 (-0.44%) ▼|DHR232.12+2.01 (+0.87%) ▲|DIS119.86+5.68 (+4.97%) ▲|DUK129.64+3.13 (+2.47%) ▲|EMR168.37+1.98 (+1.19%) ▲|FDX322.80+4.78 (+1.50%) ▲|GD363.39-11.11 (-2.97%) ▼|GE323.01+2.34 (+0.73%) ▲|GEV812.57-105.64 (-11.50%) ▼|GILD173.37+5.90 (+3.52%) ▲|GM93.09+4.75 (+5.38%) ▲|GOOG289.52+11.25 (+4.04%) ▲|GOOGL291.28+11.25 (+4.02%) ▲|GS917.09+21.00 (+2.34%) ▲|HD349.60+15.94 (+4.78%) ▲|HON226.45+2.40 (+1.07%) ▲|IBM256.19+6.15 (+2.46%) ▲|INTC57.56-3.00 (-4.95%) ▼|INTU361.98+17.26 (+5.01%) ▲|ISRG482.60+41.85 (+9.50%) ▲|JNJ272.93+6.76 (+2.54%) ▲|JPM349.84+11.86 (+3.51%) ▲|KO96.17+1.37 (+1.44%) ▲|LIN523.87+12.32 (+2.41%) ▲|LLY1,431.00+21.62 (+1.53%) ▲|LMT598.56-40.44 (-6.33%) ▼|LOW227.36+13.98 (+6.55%) ▲|LRCX225.05-5.67 (-2.46%) ▼|MA669.09+21.91 (+3.39%) ▲|MCD276.90+13.86 (+5.27%) ▲|MDLZ67.85+2.73 (+4.19%) ▲|MDT104.45+5.57 (+5.63%) ▲|META629.26+8.23 (+1.33%) ▲|MMM192.08+15.03 (+8.49%) ▲|MO78.42+1.48 (+1.92%) ▲|MRK148.47+3.80 (+2.63%) ▲|MS191.00+4.91 (+2.64%) ▲|MSFT553.68+32.69 (+6.27%) ▲|MU804.52-50.58 (-5.92%) ▼|NEE88.10+3.77 (+4.47%) ▲|NFLX66.07+2.65 (+4.17%) ▲|NKE40.67+2.19 (+5.68%) ▲|NOW109.90+0.74 (+0.68%) ▲|NVDA202.58-4.11 (-1.99%) ▼|ORCL125.60-0.59 (-0.47%) ▼|PEP143.51+6.24 (+4.55%) ▲|PFE30.52+0.52 (+1.73%) ▲|PG167.56+5.50 (+3.39%) ▲|PLTR171.38-4.02 (-2.29%) ▼|PM211.56+3.53 (+1.70%) ▲|QCOM165.57+1.14 (+0.69%) ▲|RTX195.21-8.61 (-4.22%) ▼|SBUX108.67+3.90 (+3.72%) ▲|SCHW92.63+3.35 (+3.75%) ▲|SO92.27-1.48 (-1.58%) ▼|SPG227.15+5.07 (+2.28%) ▲|T22.00+0.61 (+2.83%) ▲|TMO701.50+3.16 (+0.45%) ▲|TMUS160.11+5.70 (+3.69%) ▲|TSLA382.71-15.79 (-3.96%) ▼|TXN308.07-4.42 (-1.41%) ▼|UBER71.43+4.83 (+7.25%) ▲|UNH404.65+0.21 (+0.05%) ▲|UNP305.39+1.96 (+0.64%) ▲|UPS113.61+4.44 (+4.06%) ▲|USB60.50+0.61 (+1.02%) ▲|V432.75+12.33 (+2.93%) ▲|VZ46.41+1.17 (+2.58%) ▲|WFC86.69+1.16 (+1.35%) ▲|WMT130.01+5.15 (+4.12%) ▲|XOM170.81-6.66 (-3.75%) ▼|AAPL353.11+21.21 (+6.39%) ▲|ABBV285.72-0.28 (-0.10%) ▼|ABT114.57+5.17 (+4.73%) ▲|ACN265.25+10.69 (+4.20%) ▲|ADBE252.87+6.73 (+2.73%) ▲|AMAT370.29-11.63 (-3.05%) ▼|AMD486.66+2.76 (+0.57%) ▲|AMGN473.30+12.04 (+2.61%) ▲|AMT195.14+7.85 (+4.19%) ▲|AMZN266.71+16.02 (+6.39%) ▲|AVGO326.33-5.80 (-1.75%) ▼|AXP331.89+6.39 (+1.96%) ▲|BA176.92+3.61 (+2.08%) ▲|BAC51.57+1.91 (+3.85%) ▲|BKNG172.39+16.72 (+10.74%) ▲|BLK1,216.59+55.27 (+4.76%) ▲|BMY63.02+1.31 (+2.12%) ▲|BNY149.93+0.62 (+0.41%) ▲|BRK-B572.73+15.66 (+2.81%) ▲|C125.21+2.50 (+2.04%) ▲|CAT583.50-40.44 (-6.48%) ▼|CL99.32+3.70 (+3.87%) ▲|CMCSA24.91+1.24 (+5.22%) ▲|COF203.97-4.75 (-2.27%) ▼|COP137.90-6.50 (-4.50%) ▼|COST1,050.06+30.80 (+3.02%) ▲|CRM228.20+6.00 (+2.70%) ▲|CSCO102.61-0.36 (-0.35%) ▼|CVS81.22-10.19 (-11.15%) ▼|CVX217.92-7.35 (-3.26%) ▼|DE662.93-2.90 (-0.44%) ▼|DHR232.12+2.01 (+0.87%) ▲|DIS119.86+5.68 (+4.97%) ▲|DUK129.64+3.13 (+2.47%) ▲|EMR168.37+1.98 (+1.19%) ▲|FDX322.80+4.78 (+1.50%) ▲|GD363.39-11.11 (-2.97%) ▼|GE323.01+2.34 (+0.73%) ▲|GEV812.57-105.64 (-11.50%) ▼|GILD173.37+5.90 (+3.52%) ▲|GM93.09+4.75 (+5.38%) ▲|GOOG289.52+11.25 (+4.04%) ▲|GOOGL291.28+11.25 (+4.02%) ▲|GS917.09+21.00 (+2.34%) ▲|HD349.60+15.94 (+4.78%) ▲|HON226.45+2.40 (+1.07%) ▲|IBM256.19+6.15 (+2.46%) ▲|INTC57.56-3.00 (-4.95%) ▼|INTU361.98+17.26 (+5.01%) ▲|ISRG482.60+41.85 (+9.50%) ▲|JNJ272.93+6.76 (+2.54%) ▲|JPM349.84+11.86 (+3.51%) ▲|KO96.17+1.37 (+1.44%) ▲|LIN523.87+12.32 (+2.41%) ▲|LLY1,431.00+21.62 (+1.53%) ▲|LMT598.56-40.44 (-6.33%) ▼|LOW227.36+13.98 (+6.55%) ▲|LRCX225.05-5.67 (-2.46%) ▼|MA669.09+21.91 (+3.39%) ▲|MCD276.90+13.86 (+5.27%) ▲|MDLZ67.85+2.73 (+4.19%) ▲|MDT104.45+5.57 (+5.63%) ▲|META629.26+8.23 (+1.33%) ▲|MMM192.08+15.03 (+8.49%) ▲|MO78.42+1.48 (+1.92%) ▲|MRK148.47+3.80 (+2.63%) ▲|MS191.00+4.91 (+2.64%) ▲|MSFT553.68+32.69 (+6.27%) ▲|MU804.52-50.58 (-5.92%) ▼|NEE88.10+3.77 (+4.47%) ▲|NFLX66.07+2.65 (+4.17%) ▲|NKE40.67+2.19 (+5.68%) ▲|NOW109.90+0.74 (+0.68%) ▲|NVDA202.58-4.11 (-1.99%) ▼|ORCL125.60-0.59 (-0.47%) ▼|PEP143.51+6.24 (+4.55%) ▲|PFE30.52+0.52 (+1.73%) ▲|PG167.56+5.50 (+3.39%) ▲|PLTR171.38-4.02 (-2.29%) ▼|PM211.56+3.53 (+1.70%) ▲|QCOM165.57+1.14 (+0.69%) ▲|RTX195.21-8.61 (-4.22%) ▼|SBUX108.67+3.90 (+3.72%) ▲|SCHW92.63+3.35 (+3.75%) ▲|SO92.27-1.48 (-1.58%) ▼|SPG227.15+5.07 (+2.28%) ▲|T22.00+0.61 (+2.83%) ▲|TMO701.50+3.16 (+0.45%) ▲|TMUS160.11+5.70 (+3.69%) ▲|TSLA382.71-15.79 (-3.96%) ▼|TXN308.07-4.42 (-1.41%) ▼|UBER71.43+4.83 (+7.25%) ▲|UNH404.65+0.21 (+0.05%) ▲|UNP305.39+1.96 (+0.64%) ▲|UPS113.61+4.44 (+4.06%) ▲|USB60.50+0.61 (+1.02%) ▲|V432.75+12.33 (+2.93%) ▲|VZ46.41+1.17 (+2.58%) ▲|WFC86.69+1.16 (+1.35%) ▲|WMT130.01+5.15 (+4.12%) ▲|XOM170.81-6.66 (-3.75%) ▼|
19.7 C
New York
Wednesday, November 4, 2026

Tag: design

WIRED’s Latest Gamble—Don’t Hold Your Breath

At WIRED, they’re all about the whirlwind of change in the world, but let’s cut the fluff and get to the real deal. They’re...

NEW PRODUCT: Clog-Resistant HydroClaw® Nozzle Provides Powerful Stationary Tank Cleaning

CINCINNATI, July 23, 2025 /PRNewswire/ -- As EXAIR and BETE continue to build on a strong partnership, EXAIR has recently added a selection of BETE...

October Three Expands Operations with New Office in Indianapolis

October Three announced its expansion with a new office in Indianapolis which will service public plans, as well as non-public plans.

NANO Nuclear Completes Assembly of its Proprietary Annular Linear Induction Pump Technology Prototype for Critical Test Loop Validation in SBIR Phase III Program

Milestone demonstrates NANO Nuclear’s ability to bring advanced nuclear technology from initial design to construction and demonstration

Learn Capital Releases 2025 Outcomes Report on AI and the Future of Learning

Learn Capital's new outcomes-driven framework highlights how responsible AI investment is transforming human potential through education. IRVINE, Calif., July 23, 2025 /PRNewswire/ -- Learn Capital,...

Airvine Introduces the “WaveCore™” Flex to Address the “Outside” Backhaul Needs of Enterprise Campus Networks

The Flex complements the original WaveCore, which penetrates thick concrete floors and walls in the interior, to lower the cost of roof-to-indoor, building-to-building and...

Next Hydrogen Announces Aggregate of $1.5 million in Loans and Provides Corporate Update

MISSISSAUGA, Ontario, July 23, 2025 (GLOBE NEWSWIRE) -- Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen”) (TSXV:NXH, OTC:NXHSF), is pleased to announce that it is entering into a loan agreement with certain existing directors and officers of the Company (the “Lenders”) providing for the advance of an unsecured loan (the “Loan”) bearing interest at 5.0% per annum in the principal amount of $530,000. The Loan shall mature on the date that is one year from the advance of the Loan (the “Maturity Date”).   In conjunction with the advance of the Loan, the Company will also pay a set-up fee of $20,000 to the Lenders.

4TEEN4 Doses First Patient in Phase 1b/2a Trial of Procizumab, a Monoclonal Antibody Targeting the Biological Driver of Shock

Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal antibody, procizumab, in patients with shock caused primarily by cardiogenic events. Shock is a life-threatening condition characterized by a sudden breakdown in circulatory function due to end-stage disease or acute events, which often leads to organ failure. With only symptomatic treatment options available, shock is associated with a high mortality rate of over 50%. The Phase 1b/2a trial is designed to identify a target dose for procizumab in preparation for further clinical development. In addition, the trial will provide signals of efficacy. In a Phase 1 study in healthy volunteers, procizumab was well tolerated.

Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons

BEACHWOOD, Ohio, July 23, 2025 /PRNewswire/ -- Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company pioneering the creation of induced pluripotent stem cell (iPSC)-derived human cells...

SEGULA Technologies strengthens its presence on the African continent by opening an office in South Africa

CAPE TOWN, South Africa, July 23, 2025 /PRNewswire/ -- SEGULA Technologies officially sets up in South Africa: by opening a design office in Cape...

SEGULA Technologies strengthens its presence on the African continent by opening an office in South Africa

CAPE TOWN, South Africa, July 23, 2025 /PRNewswire/ -- SEGULA Technologies officially sets up in South Africa: by opening a design office in Cape...

Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening

Compounds developed through collaboration with Variational AI show targeted activity
Compounds developed through collaboration with Variational AI show targeted activity

Getchell Gold Corp. Commences Drill Program at Fondaway Canyon, Nevada

VANCOUVER, BC, July 23, 2025 /CNW/ - Getchell Gold Corp. (CSE: GTCH) (OTCQB: GGLDF) (FWB: GGA1) ("Getchell" or the "Company") is pleased to announce...

L’Oréal Turkey Partners with AdCreative.ai to Power Scalable, High-Performing Visual Content

Beauty meets intelligent tech: L'Oréal Turkey unlocks faster, more consistent creative production with AdCreative.ai ISTANBUL and PARIS, July 23, 2025 /PRNewswire/ -- L'Oréal Turkey has partnered with...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDesign